Osterweis Capital Management Inc. Purchases New Holdings in GlaxoSmithKline plc (GSK)

Share on StockTwits

Osterweis Capital Management Inc. purchased a new stake in shares of GlaxoSmithKline plc (NYSE:GSK) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 5,000 shares of the pharmaceutical company’s stock, valued at approximately $202,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. We Are One Seven LLC grew its holdings in GlaxoSmithKline by 185.1% during the 1st quarter. We Are One Seven LLC now owns 2,677 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 1,738 shares in the last quarter. Kiley Juergens Wealth Management LLC purchased a new position in shares of GlaxoSmithKline in the 2nd quarter worth approximately $113,000. Adviser Investments LLC purchased a new position in shares of GlaxoSmithKline in the 1st quarter worth approximately $117,000. Toronto Dominion Bank boosted its holdings in shares of GlaxoSmithKline by 133.3% in the 1st quarter. Toronto Dominion Bank now owns 3,150 shares of the pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,800 shares during the period. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of GlaxoSmithKline in the 2nd quarter worth approximately $134,000. Institutional investors and hedge funds own 11.03% of the company’s stock.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline purchased 80,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 17th. The stock was purchased at an average cost of $12.50 per share, with a total value of $1,000,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have purchased a total of 498,048 shares of company stock valued at $6,136,988 over the last three months. 10.00% of the stock is owned by corporate insiders.

Shares of GSK stock opened at $40.34 on Wednesday. GlaxoSmithKline plc has a 52-week low of $34.52 and a 52-week high of $42.36. The company has a debt-to-equity ratio of 8.13, a current ratio of 0.94 and a quick ratio of 0.61. The company has a market cap of $100.44 billion, a P/E ratio of 14.01, a price-to-earnings-growth ratio of 2.00 and a beta of 0.86.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 25th. The pharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.06. GlaxoSmithKline had a return on equity of 159.74% and a net margin of 5.51%. The firm had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.47 billion. research analysts expect that GlaxoSmithKline plc will post 2.94 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 11th. Investors of record on Friday, August 10th will be paid a dividend of $0.496 per share. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.92%. The ex-dividend date is Thursday, August 9th. GlaxoSmithKline’s dividend payout ratio is currently 68.75%.

GSK has been the subject of a number of recent research reports. Zacks Investment Research cut GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Friday, June 8th. Liberum Capital cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, August 30th. DZ Bank reiterated a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, June 14th. Deutsche Bank reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, August 1st. Finally, TheStreet upgraded GlaxoSmithKline from a “c” rating to a “b” rating in a report on Monday, August 6th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus price target of $41.57.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: Fundamental Analysis and Individual Investors

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply